These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 33807511)

  • 1. Phosphodiesterases Expression during Murine Cardiac Development.
    Carvalho TMDCS; Cardarelli S; Giorgi M; Lenzi A; Isidori AM; Naro F
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydrolysis of N-methyl-D-aspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus.
    Suvarna NU; O'Donnell JM
    J Pharmacol Exp Ther; 2002 Jul; 302(1):249-56. PubMed ID: 12065724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The calcium/calmodulin-dependent phosphodiesterase PDE1C down-regulates glucose-induced insulin secretion.
    Han P; Werber J; Surana M; Fleischer N; Michaeli T
    J Biol Chem; 1999 Aug; 274(32):22337-44. PubMed ID: 10428803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in phosphodiesterase activity in the developing rat submandibular gland.
    Tanaka S; Shimooka S; Shimomura H
    Arch Oral Biol; 2002 Aug; 47(8):567-76. PubMed ID: 12221013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation.
    Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
    Cell Mol Biol Lett; 2005; 10(2):305-19. PubMed ID: 16010295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cyclic nucleotide phosphodiesterases: therapeutic targets in cardiac hypertrophy and failure].
    Barthou A; Kamel R; Leroy J; Vandecasteele G; Fischmeister R
    Med Sci (Paris); 2024; 40(6-7):534-543. PubMed ID: 38986098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of substrate specificity determinants in human cAMP-specific phosphodiesterase 4A by single-point mutagenesis.
    Richter W; Unciuleac L; Hermsdorf T; Kronbach T; Dettmer D
    Cell Signal; 2001 Mar; 13(3):159-67. PubMed ID: 11282454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiplicity within cyclic nucleotide phosphodiesterases.
    Rybalkin SD; Beavo JA
    Biochem Soc Trans; 1996 Nov; 24(4):1005-9. PubMed ID: 8968501
    [No Abstract]   [Full Text] [Related]  

  • 9. Evidence for the activity of five adenosine-3',5'-monophosphate-degrading phosphodiesterase isozymes in the adult rat neocortex.
    Sutor B; Mantell K; Bacher B
    Neurosci Lett; 1998 Aug; 252(1):57-60. PubMed ID: 9756358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases.
    Kokkonen K; Kass DA
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():455-479. PubMed ID: 27732797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dexamethasone down-regulates cAMP-phosphodiesterase in human osteosarcoma cells.
    Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
    Biochem Pharmacol; 2005 Jan; 69(2):267-75. PubMed ID: 15627479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
    Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
    Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway.
    Eckly AE; Lugnier C
    Br J Pharmacol; 1994 Oct; 113(2):445-50. PubMed ID: 7834194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclic nucleotide phosphodiesterase-mediated integration of cGMP and cAMP signaling in cells of the cardiovascular system.
    Maurice DH
    Front Biosci; 2005 May; 10():1221-8. PubMed ID: 15769620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "cAMP-specific" phosphodiesterase contributes to cGMP degradation in cerebellar cells exposed to nitric oxide.
    Bellamy TC; Garthwaite J
    Mol Pharmacol; 2001 Jan; 59(1):54-61. PubMed ID: 11125024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two isoforms of cGMP-inhibited cyclic nucleotide phosphodiesterases in human tissues distinguished by their responses to vesnarinone, a new cardiotonic agent.
    Masuoka H; Ito M; Sugioka M; Kozeki H; Konishi T; Tanaka T; Nakano T
    Biochem Biophys Res Commun; 1993 Jan; 190(2):412-7. PubMed ID: 8381275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclic nucleotide hydrolysis in bovine aortic endothelial cells in culture: differential regulation in cobblestone and spindle phenotypes.
    Keravis T; Komas N; Lugnier C
    J Vasc Res; 2000; 37(4):235-49. PubMed ID: 10965223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carboxyamidotriazole: a novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases.
    Guo L; Luo L; Ju R; Chen C; Zhu L; Li J; Yu X; Ye C; Zhang D
    Eur J Pharmacol; 2015 Jan; 746():14-21. PubMed ID: 25446933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isoforms of cyclic nucleotide phosphodiesterase PDE3 and their contribution to cAMP hydrolytic activity in subcellular fractions of human myocardium.
    Hambleton R; Krall J; Tikishvili E; Honeggar M; Ahmad F; Manganiello VC; Movsesian MA
    J Biol Chem; 2005 Nov; 280(47):39168-74. PubMed ID: 16172121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.